Clinical trials: Placebo Response
Placebo Effect, Physical Performance
Effects of Conditioning Activities in Female Athletes
This study will investigate how different warm-up strategies affect physical performance in female athletes who practice invasion sports (e.g., soccer, handball, and basketball).
- Conditions
- Placebo Effect, Physical Performance, Countermovement Jump
- Trial name
- NCT07542119
- Testing
- post-activation performance enhancement (PAPE) protocol
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Triangulo Mineiro
Asthma
Safety and Efficacy of WIN-901X in Asthma
This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.
- Trial name
- NCT01820481
- Testing
- WIN-901X dose level 1, WIN-901X dose level 2, WIN-901X dose level 3
- Where
- South Korea
- Volunteers
- 209 people
- Sponsor
- Whanin Pharmaceutical Company
Atopic Dermatitis (AD)
PRA-216 Atopic Dermatitis Safety and Efficacy Study
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)
- Trial name
- NCT07810777
- Testing
- Active PRA-216
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 39 people
- Sponsor
- Prana Therapies Inc
Asthma
One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids
The primary objective of this study is to evaluate efficacy of AZD1981 in uncontrolled asthmatic patients on maintenance inhaled glucocorticosteroids.
- Trial name
- OLIVE (NCT00758589)
- Testing
- AZD1981
- Where
- 21 sites in Argentina, Brazil and 2 more
- Volunteers
- 368 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases
Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Prevention of Cardiovascular Disease
Resveratrol can exhibit benefits against cardiovascular diseases (CVDs) although the cardioprotective role of resveratrol as part of the human diet is not yet clear.
- Trial name
- FUNGRAPE (NCT01449110)
- Testing
- Grape extract in primary prevention (PP), Grape extract in SP, Resveratrol-enriched grape extract in PP
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- National Research Council, Spain
Severe Sepsis
AZD9773 Dose Escalation Study
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773)…
- Trial name
- NCT00615017
- Testing
- AZD9773 (CytoFab)
- Where
- 26 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac
Studying Complement Inhibition in Complex Cardiac Surgery
The trial enrolls patients undergoing a complex cardiac surgery. The primary goal of the trial is to evaluate the pharmacodynamic dose response relationship of the monoclonal antibody IFX-1 in these patients.
- Trial name
- CARDIAC (NCT02866825)
- Testing
- IFX-1
- Where
- 10 sites in Germany
- Volunteers
- 116 people
- Sponsor
- InflaRx GmbH
Generalized Anxiety Disorder (GAD)
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- NCT06846320
- Testing
- ABBV-932, Antidepressant Therapy (ADT)
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- AbbVie
Healthy Adults
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated agonists of the glucocorticoid…
- Trial name
- NCT02767089
- Testing
- Prednisone
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Device Study in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of two different devices that may be used to inject medication just under the skin. Participants will receive placebo; no active drug will be given.
- Trial name
- NCT04848402
- Testing
- On-Body Delivery System (OBDS)/Multiple Bolus Injector, Single Auto Injector
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS)
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
This is a Phase 3, randomized, blinded, and placebo-controlled clinical trial investigating a new combination treatment for critically ill adults who have severe community-acquired pneumonia, especially if they also have sepsis…
- Conditions
- Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia
- Trial name
- NCT07492875
- Testing
- Nogapendekin alfa inbakicept (NAI), agenT-797
- Sponsor
- ImmunityBio, Inc.
Rheumatoid Arthritis
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
To compare the maintenance of efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with or without other disease modifying antirheumatic drugs therapy with that of methotrexate with or without other…
- Trial name
- NCT01578850
- Testing
- Etanercept
- Where
- 62 sites in Brazil, China and 17 more
- Volunteers
- 491 people
- Sponsor
- Pfizer
HIV Infections
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
To evaluate the safety and immunogenicity of live recombinant canarypox ALVAC-HIV vCP205 in combination with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) at 80 microg and 250 microg.
- Trial name
- NCT00001090
- Testing
- APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim
- Where
- 4 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metabolism and Nutrition Disorder, Obesity
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC…
- Trial name
- NCT01044108
- Testing
- NNC 0070-0002-0453, '2-0453
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
HIV Infections
Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
The purpose of this study is to determine the safety and the immune responses to the HIV vaccine candidate, MVA-CMDR. This vaccine was designed to induce immune responses to three HIV "passenger" genes encoded with the viral…
- Trial name
- NCT00376090
- Testing
- MVA-CMDR
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Type 2 Diabetes
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic…
- Trial name
- NCT00143520
- Testing
- Rivoglitazone, Pioglitazone
- Where
- 74 sites in United States
- Volunteers
- 441 people
- Sponsor
- Daiichi Sankyo
Psoriasis
Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis
The overall purpose of this trial is to assess efficacy and safety of the combination of low doses of Methotrexate (MTX) with anti Tumor Necrosis Factor (TNF) alpha to improve initial efficacy and maintenance rate of anti-TNF…
- Trial name
- METHOBIO (NCT02829424)
- Testing
- Methotrexate
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Asthma
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from…
- Trial name
- NCT01128595
- Testing
- FF/GW642444M, GW642444M, Fluticasone Furoate
- Where
- 4 sites in Australia, New Zealand and 1 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease
A Study of Abatacept in Patients With Active Crohn's Disease
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies.
- Trial name
- NCT00406653
- Testing
- abatacept
- Where
- 101 sites in United States, Australia and 15 more
- Volunteers
- 451 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess the postprandial glucodynamic response to 2 doses of insulin glargine/lixisenatide fixed-ratio combination compared to placebo in Japanese patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02713477
- Testing
- Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010, Insulin glargine HOE901
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.